Skip to main content
. 2019 May 7;25:3374–3389. doi: 10.12659/MSM.914085

Figure 9.

Figure 9

The RFS of 4.1B in BC. (A) High mRNA level of 4.1B was not associated with longer RFS in all BC patients. (B, C) High mRNA level of 4.1B was not associated with longer RFS both in ER-positive and ER-negative BC patients. (D–G) High mRNA level of 4.1B was not associated with longer RFS in basal-like, luminal A, luminal B, or HER2+ BC patients. (H) High mRNA level of 4.1B was associated with worse RFS in Her-2-positive subtype BC patients with chemotherapy.